Celgene Sr. Manager, US Forecasting in Summit, New Jersey
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
The Senior Manager-US Business Planning & Analysis will provide support and strategic insights to key business leaders to maximize financial performance. This includes ongoing financial analysis, value-added reporting, and business enhancing analytics. The primary activities include collaborating with internal stakeholders across the US and Global Hematology/Oncology organizations to support quarterly submissions of US revenue projections, as well as Latest Estimate (LE) and Long Range Plan (LRP) updates for Senior Management. The Senior Manager is expected to be an active business partner in support of critical business decisions. Other responsibilities will include forecast support of key in-line and launch brands, consolidation & reporting of key BP&A deliverables, understanding & measuring key drivers of the business, as well as ad hoc assignments. This person will be an individual contributor and be part of the Business Planning & Analysis Team within US Strategic Planning & Decision Analysis.
Responsibilities include, but are not limited to, the following:
Meet all US & Global business reporting requirements on a timely basis. Ensure all financial data outputs are accurate and formatted correctly.
Supports US Marketing Teams by providing regular updates of in-line forecasts and sales performance. Provides proactive communication to all stakeholders of any significant event or activity that could have a financial impact
Provide sales reporting analytics to maximize product and portfolio performance.
Collaborates with Global to provide relevant reporting for the Board of Directors and Investor Relations meetings.
Participates on cross-functional teams whose members consist of US Marketing, Sales, Market Research, Data Analytics & Enablement, Business Development, Manufacturing, Finance and Global Marketing.
Partners with US Marketing, Data Analytics & Enablement, Market Access and Field Sales to identify, analyze and interpret key market, competitive and promotional trends and their impact on current and future product opportunities and financial performance.
Collaborates with Finance and Market Access to share information for gross-to-net forecasts and other key financial assumptions.
Regular deliverables include sales projections for the current quarter, Latest Estimates, Budget, 5-year Long-Range Plan and Demand forecasts. Responsible for the planning, execution and presentation of key BP&A deliverables. Help identify process improvements to increase efficiencies.
Brings strategic direction to the Analytics Team and helps drives innovation to find new forecasting approaches & techniques, as well as reporting enhancements.
This job requires an individual, who:
Works well cross-functionally to help set expectations and build alignment on forecasts and forecasts deliverables, and to help ensure the consistent understanding of the financials once reported.
Proactively identifies knowledge gaps and identifies a path forward in filling those gaps.
Works closely with the cross functional US teams and other key stakeholders in the development and reporting of all BP&A deliverables.
Delivers accurate, insightful, and well supported financial analytics to the Hematology/Oncology Franchise within established timelines.
Understands and thrives working across multiple complex markets.
Generates insights from multiple data sources that may often be perceived as ambiguous.
Partners with marketing teams, competitive intelligence, outside agencies, Sales Operations and other critical cross functional teams to help support the US Hematology/Oncology Franchise.
BS/BA required; MBA-Finance preferred
5+ years of biotech/pharma industry experience with relevant experience in Business Analysis, Forecasting and Financial Analysis. Hematology / Oncology markets experience a plus.
In-depth strategic thinking and creative problem solving skills.
Excellent communications skills: written, oral and presentation skills
Excellent interpersonal skills. Team player, who builds relationships and works easily with a variety of functions.
Strong analytical and organizational skills, with the ability to manage multiple projects simultaneously.
Results-oriented. Excellent follow-through habits.
High proficiency in personal computer technology and various software packages including Microsoft Excel, Word, and PowerPoint and other programs as needed. Hyperion experience a plus.
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.